The Comirnaty COVID vaccine has met the MHRA’s required safety, quality and effectiveness standards to be authorised for use in this age group.
The authorisation has today been granted for a new presentation of the Pfizer/BioNTech COVID-19 vaccine (Comirnaty) for use in infants and children aged 6 months to 4 years.
The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the vaccine in this new age group after it was found to meet the UK regulator’s standards of safety, quality and effectiveness, with no new safety concerns identified. The Commission on Human Medicines has endorsed this decision after a careful review of the evidence.
This presentation is specially designed for this new age group and given at a lower dose compared to that used in individuals aged 5 to 11 years (3 micrograms compared with 10 micrograms). It is given as three injections in the upper arm, with the first two doses given 3 weeks apart, followed by a third dose given at least 8 weeks after the second dose.
In reaching their decision, the MHRA’s experts carefully reviewed data from an ongoing clinical trial involving 4,526 participants. The common, expected side effects (reactogenicity) were in keeping with what can be anticipated from a vaccine in this age group.
It will be for the Joint Committee on Vaccination and Immunisation (JCVI) to determine if the vaccine will be recommended for use in this age group as part of the UK’s COVID-19 vaccination programme.